Physician profile
Seyoum Daffo Bage
NPI 1609842640
$5,500.43
in general payments reported to CMS, 2019-2025
21 companies · $76.12 in 2025
The $76.12 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $471 · 2021: $1,042 · 2022: $682 · 2023: $1,069 · 2024: $1,126 · 2025: $76.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.33 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,061.28 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Melinta Therapeutics, LLC | $1,000.66 | 2019-2024 | Kimyrsa, Rezzayo, Vabomere |
| Gilead Sciences, INC. | $724.17 | 2019-2024 | |
| Insmed, INC. | $692.17 | 2019-2024 | Arikayce |
| Viiv Healthcare Company | $424.29 | 2019-2024 | Apretude, Dovato |
| Abbvie INC. | $423.64 | 2020-2025 | Dalvance, Mavyret, Teflaro |
| Tetraphase Pharmaceuticals, INC. | $189.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.83 | 2021-2023 | Hyqvia, Gattex |
| Shionogi INC | $141.25 | 2021-2024 | Fetroja |
| Allergan, INC. | $138.84 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $124.74 | 2019-2024 | Nuzyra |
| La Jolla Pharmaceutical Company | $86.98 | 2021-2024 | Xerava |
| Organogenesis INC. | $79.55 | 2019 | |
| Xeris Pharmaceuticals, INC. | $53.23 | 2024 | Recorlev |
| Theratechnologies INC. | $46.20 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $42.84 | 2022 | |
| Aimmune Therapeutics, INC. | $29.74 | 2023 | |
| Accelerate Diagnostics INC. | $25.52 | 2023 | |
| Shire North American Group INC | $20.68 | 2019 | |
| Boston Scientific Corporation | $19.11 | 2025 | General - Therapies |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seyoum Bage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.